Harmony Biosciences to Announce Q3 2024 Financial Results
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is preparing to release its financial results for the third quarter of 2024 on an upcoming Tuesday, just before the trading day commences. This exciting announcement is sure to shed light on various operational aspects and future endeavors of the company.
Details of the Financial Announcement
The anticipated announcement will be made available to the public prior to the opening of financial markets. To offer insights into the reported results, the company will conduct a conference call and an online webcast on the same day. The presentation is designed to provide stakeholders with a comprehensive understanding of the financial performance and strategic directions of Harmony Biosciences.
Conference Call Participation
Individuals interested in participating in this insightful call are encouraged to dial in a little ahead of the start time. There will be two options to join: a domestic line at (800) 245-3047 and an international line at (203) 518-9765. A reference passcode will be provided to ensure smooth entry into the call.
Accessing the Webcast
For those unable to join live, Harmony Biosciences will make a replay of the conference call accessible via the company’s investor relations webpage. This ensures that all interested parties can catch up on any important updates at their convenience.
About Harmony Biosciences
Harmony Biosciences is a dedicated pharmaceutical company focused on developing and marketing groundbreaking therapies for patients suffering from rare neurological conditions that currently face significant treatment gaps. The company was established by Paragon Biosciences, LLC in 2017, and it thrives on innovation and compassion, with a central aim to create therapeutic solutions that genuinely uplift the lives of individuals affected by these rare diseases.
Company Values and Vision
Empathy and imagination drive Harmony Biosciences, forging a path toward a future filled with new therapeutic possibilities. The organization believes that when these elements intersect, they can enact profound changes in the community and pave the way for better health outcomes. The passion for innovation and patient care is reflected in every step of their research and development journey.
Connecting with Investors
For more inquiries, Harmony Biosciences has set up dedicated channels for both investors and media contacts. The investor team is led by Brennan Doyle, contactable at 484-539-9700 for all investment-related queries. Similarly, media inquiries can be directed to Cate McCanless, whose phone number is 202-641-6086.
Continuous Engagement and Future Plans
Harmony Biosciences remains committed to maintaining a proactive communication stream with its investors and the broader community. Regular updates, strategies, and advancements will be shared to keep stakeholders informed about the exciting developments in their pipeline.
Frequently Asked Questions
1. When will Harmony Biosciences report its Q3 2024 results?
Harmony Biosciences plans to report its Q3 2024 financial results on October 29, 2024.
2. How can I join the conference call?
You can join the conference call by dialing (800) 245-3047 for domestic calls and (203) 518-9765 for international calls.
3. Where can I access the company’s investor relations information?
The investor relations information is available on the Harmony Biosciences website.
4. Who should I contact for investor-related inquiries?
Brennan Doyle can be contacted at 484-539-9700 for investor-related questions.
5. What is Harmony Biosciences focused on?
Harmony Biosciences focuses on developing therapies for patients with rare neurological diseases that have significant unmet medical needs.
